<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01197495</url>
  </required_header>
  <id_info>
    <org_study_id>JULIDO-002</org_study_id>
    <nct_id>NCT01197495</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of Juvederm(R) Ultra XC Injectable Gel for Lip Augmentation</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the safety and effectiveness of Juvederm(R) Ultra
      XC Injectable Gel for lip augmentation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects were randomized to either the treatment group, Juvederm(R) Ultra XC Injectable
      Gel, or to the control group (no treatment). At month 3, subjects in the control group
      crossed over to the treatment group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With ≥1-Point Improvement on the Investigator Assessed 5-point Lip Fullness Scale 2 (LFS2)</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>Overall lip fullness is assessed by the blinded Evaluating Investigator compared to baseline using the 5-point LFS2. Scores range from 1=minimal improvement to 5=very marked improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With ≥1-Point Improvement on the Perioral Line (POL) Severity Scale</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>Subject's upper lip perioral lines are assessed compared to baseline using the 4-point validated POL Severity Scale. Scores range from 0=None (best) to 3=Severe (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Oral Commissures With ≥1-Point Improvement on the Oral Commissures Severity (OCS) Scale</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>Subject's right and left oral commissures are assessed compared to baseline using the validated OCS Scale. Scores range from 0=none (best) to 3=severe (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving Their Personal Treatment Goal of Overall Lip Fullness</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>Subjects assessed their personal treatment goal of overall lip fullness as 'achieved' or 'not achieved.'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration Effect of Treatment on Lip Fullness</measure>
    <time_frame>Month 1, Month 3, Month 6, Month 7.5, Month 9, Month 10.5, Month 12</time_frame>
    <description>Duration of treatment effect on lip fullness is assessed by the blinded Evaluating Investigator as ≥1-point Improvement from baseline in overall lip fullness of the eligible lip at each visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">213</enrollment>
  <condition>Lip Augmentation</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Juvederm(R) Ultra XC Injectable Gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No treatment for 3 months followed by Juvederm(R) Ultra XC Injectable Gel at Month 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>hyaluronic acid gel</intervention_name>
    <description>Dosage per Investigator's discretion to obtain lip treatment gel; 1 touch-up treatment is allowed 14 to 30 days after initial treatment. Repeat treatment occurs at month 12. Subjects in the control group start with treatment at month 3. Maximum total volume per subject is 4.8 mL for initial and touch-up treatment combined.</description>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>Juvederm(R) Ultra XC Injectable Gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18 years of age or older

          -  Desire augmentation of his/her lips

          -  Have a pre-treatment score of Minimal or Mild

        Exclusion Criteria:

          -  Have lip tattoos, facial hair or scars that would interfere with visualization of the
             lips and perioral area for the effectiveness assessments

          -  Have dentures or any device covering all or part of the upper palate, and/or severe
             malocclusion, dentofacial or maxillofacial deformities, or significant asymmetry of
             the lips and perioral area, as judged by the Treating Investigator

          -  Have undergone oral surgery or other dental procedures (e.g., tooth extraction,
             orthodontia, or implantation) within 30 days prior to enrollment or be planning to
             undergo any of these procedures during the study

          -  Have ever undergone facial plastic surgery or received semi-permanent fillers or
             permanent facial implants (e.g., calcium hydroxylapatite, L-polylactic acid, PMMA,
             silicone, ePTFE) anywhere in the face or neck, or be planning to be implanted with any
             of these products at any time during the study

          -  Have undergone temporary dermal filler treatment within 24 months prior to study entry
             or be planning to undergo any of these procedures at any time during the study

          -  Have undergone cosmetic facial procedures, e.g., resurfacing (laser photomodulation,
             intense pulsed light, radio frequency, dermabrasion, chemical peel, or other ablative
             or non-ablative procedures) or mesotherapy anywhere in the face or neck, or BOTOX®
             Cosmetic injections in the lower face (below the orbital rim), within 6 months prior
             to entry in the study or be planning to undergo any of these procedures at any time
             during the study

          -  Begin use of any new over-the-counter or prescription, oral or topical, anti-wrinkle
             products for the lips or around the mouth within 3 months (90 days) prior to
             enrollment or be planning to begin use of such products at any time during the study
             [NOTE: use of sunscreens and continued therapy with some cosmeceuticals (e.g., alpha
             hydroxy acids, glycolic acids, retinol, or retinoic acids) is allowed if the regimen
             was established ≥ 3months (90 days) prior to enrollment and the regimen remains
             unchanged during the study

          -  Have a history of anaphylaxis, multiple severe allergies, atopy, allergy to lidocaine,
             hyaluronic acid products or Streptococcal protein, or be planning to undergo
             desensitization therapy during the term of the study

          -  Have an active inflammation, infection, cancerous or pre-cancerous lesion, or unhealed
             wound in the mouth area

          -  Be on an ongoing regimen of anti-coagulation therapy (e.g., warfarin) or have taken
             NSAIDS (e.g., aspirin, ibuprofen) or other substances known to increase coagulation
             time (e.g., herbal supplements with garlic or gingko) within 10 days of undergoing
             study device injections [Study device injections may be delayed as necessary to
             accommodate this 10-day washout period.]

          -  Be pregnant, lactating, or planning to become pregnant at any time during the study

          -  Have received investigational product within 30 days prior to study enrollment or be
             planning to participate in another investigation during the course of this study

          -  Be an employee (or immediate relative of an employee) of the Treating Investigator,
             Evaluating Investigator, Sponsor or representative of the Sponsor

          -  Have a condition or be in a situation that, in the Investigator's opinion, may put the
             subject at significant risk, may confound the study results, or may interfere
             significantly with the subject's participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2010</study_first_submitted>
  <study_first_submitted_qc>September 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2010</study_first_posted>
  <results_first_submitted>December 1, 2015</results_first_submitted>
  <results_first_submitted_qc>April 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 7, 2016</results_first_posted>
  <last_update_submitted>April 29, 2016</last_update_submitted>
  <last_update_submitted_qc>April 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The modified intent-to-treat (mITT) population is presented and includes all treated subjects.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>Juvederm(R) Ultra XC Injectable Gel</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>No treatment for 3 months followed by Juvederm(R) Ultra XC Injectable Gel at Month 3.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="157"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>Juvederm(R) Ultra XC Injectable Gel</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>No treatment for 3 months followed by Juvederm(R) Ultra XC Injectable Gel at Month 3.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="157"/>
            <count group_id="B2" value="56"/>
            <count group_id="B3" value="213"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.6" spread="11.46"/>
                    <measurement group_id="B2" value="49.2" spread="9.72"/>
                    <measurement group_id="B3" value="48.8" spread="11.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With ≥1-Point Improvement on the Investigator Assessed 5-point Lip Fullness Scale 2 (LFS2)</title>
        <description>Overall lip fullness is assessed by the blinded Evaluating Investigator compared to baseline using the 5-point LFS2. Scores range from 1=minimal improvement to 5=very marked improvement.</description>
        <time_frame>Baseline, Month 3</time_frame>
        <population>Modified Intent-to-Treat: all treated subjects with data at the designated time point</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Juvederm(R) Ultra XC Injectable Gel</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No treatment for 3 months followed by Juvederm(R) Ultra XC Injectable Gel at Month 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With ≥1-Point Improvement on the Investigator Assessed 5-point Lip Fullness Scale 2 (LFS2)</title>
          <description>Overall lip fullness is assessed by the blinded Evaluating Investigator compared to baseline using the 5-point LFS2. Scores range from 1=minimal improvement to 5=very marked improvement.</description>
          <population>Modified Intent-to-Treat: all treated subjects with data at the designated time point</population>
          <units>Percentage of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.1" lower_limit="71.43" upper_limit="85.56"/>
                    <measurement group_id="O2" value="26.1" lower_limit="14.27" upper_limit="41.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With ≥1-Point Improvement on the Perioral Line (POL) Severity Scale</title>
        <description>Subject's upper lip perioral lines are assessed compared to baseline using the 4-point validated POL Severity Scale. Scores range from 0=None (best) to 3=Severe (worst).</description>
        <time_frame>Baseline, Month 3</time_frame>
        <population>Subjects treated for POL at the designated time points</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Juvederm(R) Ultra XC Injectable Gel</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With ≥1-Point Improvement on the Perioral Line (POL) Severity Scale</title>
          <description>Subject's upper lip perioral lines are assessed compared to baseline using the 4-point validated POL Severity Scale. Scores range from 0=None (best) to 3=Severe (worst).</description>
          <population>Subjects treated for POL at the designated time points</population>
          <units>Percentage of Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Oral Commissures With ≥1-Point Improvement on the Oral Commissures Severity (OCS) Scale</title>
        <description>Subject's right and left oral commissures are assessed compared to baseline using the validated OCS Scale. Scores range from 0=none (best) to 3=severe (worst).</description>
        <time_frame>Baseline, Month 3</time_frame>
        <population>Subjects treated for OCS at the designated time points</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Juvederm(R) Ultra XC Injectable Gel</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Oral Commissures With ≥1-Point Improvement on the Oral Commissures Severity (OCS) Scale</title>
          <description>Subject's right and left oral commissures are assessed compared to baseline using the validated OCS Scale. Scores range from 0=none (best) to 3=severe (worst).</description>
          <population>Subjects treated for OCS at the designated time points</population>
          <units>Percentage of Oral Commissures</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Oral Commissures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Achieving Their Personal Treatment Goal of Overall Lip Fullness</title>
        <description>Subjects assessed their personal treatment goal of overall lip fullness as 'achieved' or 'not achieved.'</description>
        <time_frame>Baseline, Month 3</time_frame>
        <population>Treated subjects in the Treatment group</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Juvederm(R) Ultra XC Injectable Gel</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving Their Personal Treatment Goal of Overall Lip Fullness</title>
          <description>Subjects assessed their personal treatment goal of overall lip fullness as 'achieved' or 'not achieved.'</description>
          <population>Treated subjects in the Treatment group</population>
          <units>Percentage of Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration Effect of Treatment on Lip Fullness</title>
        <description>Duration of treatment effect on lip fullness is assessed by the blinded Evaluating Investigator as ≥1-point Improvement from baseline in overall lip fullness of the eligible lip at each visit.</description>
        <time_frame>Month 1, Month 3, Month 6, Month 7.5, Month 9, Month 10.5, Month 12</time_frame>
        <population>Modified Intent-to-Treat: all treated subjects with data at the designated time point</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Juvederm(R) Ultra XC Injectable Gel</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No treatment for 3 months followed by Juvederm(R) Ultra XC Injectable Gel at Month 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration Effect of Treatment on Lip Fullness</title>
          <description>Duration of treatment effect on lip fullness is assessed by the blinded Evaluating Investigator as ≥1-point Improvement from baseline in overall lip fullness of the eligible lip at each visit.</description>
          <population>Modified Intent-to-Treat: all treated subjects with data at the designated time point</population>
          <units>% of Pts Retaining ≥1-point Improvement</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.5" lower_limit="89.53" upper_limit="97.38"/>
                    <measurement group_id="O2" value="98.0" lower_limit="94.00" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (N=114, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.5" lower_limit="70.78" upper_limit="84.13"/>
                    <measurement group_id="O2" value="77.3" lower_limit="65.42" upper_limit="89.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (N=99, 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.1" lower_limit="61.64" upper_limit="76.54"/>
                    <measurement group_id="O2" value="74.8" lower_limit="62.34" upper_limit="87.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7.5 (N=89, 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.4" lower_limit="56.51" upper_limit="72.20"/>
                    <measurement group_id="O2" value="63.9" lower_limit="49.37" upper_limit="78.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (N=75, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.1" lower_limit="45.58" upper_limit="62.54"/>
                    <measurement group_id="O2" value="55.4" lower_limit="39.97" upper_limit="70.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10.5 (N=69, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9" lower_limit="40.29" upper_limit="57.53"/>
                    <measurement group_id="O2" value="45.8" lower_limit="29.64" upper_limit="61.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (N=51, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1" lower_limit="36.32" upper_limit="53.78"/>
                    <measurement group_id="O2" value="36.6" lower_limit="16.02" upper_limit="57.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>208 subjects includes subjects who received initial treatment in both groups (157 in the treatment group and 51 in the control group).
114 subjects includes subjects who had repeat treatment from both treatment groups.</desc>
      <group_list>
        <group group_id="E1">
          <title>Onset Prior to Repeat Treatment</title>
          <description>Juvederm(R) Ultra XC Injectable Gel</description>
        </group>
        <group group_id="E2">
          <title>Onset After Repeat Treatment</title>
          <description>Juvederm(R) Ultra XC Injectable Gel</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Development Hip Dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Squamous Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Premature Baby</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Mass</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Injection Site Induration</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Allergan Inc.,</name_or_title>
      <organization>Allergan, Inc</organization>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

